Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
This collaboration turns kitting into a strategic advantage for sponsors and sites
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Fenebrutinib targets cells in the immune system known as B cells and microglia
The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance
Subscribe To Our Newsletter & Stay Updated